Secretory Mucin MUC5AC in Gastrointestinal Malignancies

Total Page:16

File Type:pdf, Size:1020Kb

Secretory Mucin MUC5AC in Gastrointestinal Malignancies University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-7-2016 Secretory Mucin MUC5AC in Gastrointestinal Malignancies Shiv Ram Krishn University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, and the Molecular Biology Commons Recommended Citation Krishn, Shiv Ram, "Secretory Mucin MUC5AC in Gastrointestinal Malignancies" (2016). Theses & Dissertations. 110. https://digitalcommons.unmc.edu/etd/110 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. Secretory mucin MUC5AC in gastrointestinal malignancies by SHIV RAM KRISHN A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry & Molecular Biology Graduate Program Under the supervision of Dr. Surinder K. Batra University of Nebraska Medical Center Omaha, Nebraska April, 2016 Supervisory Committee: Dr. Michael A. Hollingsworth, Ph.D. Dr. Vimla Band, Ph.D. Parmender P. Mehta, Ph.D. Dr. Chittibabu Guda, Ph.D. Dr. Maneesh Jain, Ph.D. i Secretory mucin MUC5AC in gastrointestinal malignancies Shiv Ram Krishn, Ph.D. University of Nebraska, 2016 Advisor: Dr. Surinder K Batra, Ph.D. Secretory mucin MUC5AC is an extensively glycosylated high molecular weight protein that forms a polymeric gel layer over the epithelial layers under physiological conditions to protect these surfaces from myriad of insults. MUC5AC is known to be implicated in various malignancies including pancreatic cancer and colorectal cancer. It is overexpressed in pancreatic cancer compared to no expression in the normal pancreas. However, its functional implications and associated mechanistic basis in pancreatic cancer remain obscure. Therefore, we investigated the role of MUC5AC in initiation and progression of pancreatic cancer. Our study showed that MUC5AC expression is elevated during pancreatic cancer progression while it was not detected in the normal pancreas. To elucidate the functional role of MUC5AC in pancreatic cancer, we performed MUC5AC knockdown studies in pancreatic cancer cell lines (FG/COLO357, SW1990). Knockdown of MUC5AC decreased pancreatic cancer cell viability, tumorigenicity, metastasis, angiogenesis, and increased sensitivity to Gemcitabine. We observed that MUC5AC might impact pancreatic cancer cell growth and metastasis by its interactions with E-Cadherin and β-Catenin. To further elaborate the functional role of MUC5AC, we developed the KrasG12D; Pdx1-Cre; Muc5ac-/- mouse model by crossing Muc5ac-/- mice with pancreatic cancer mice model- KrasG12D; Pdx1-Cre mice. A delay in the onset as well as the progression of pancreatic cancer was observed in KrasG12D; Pdx1-Cre; Muc5ac-/- mice as compared to the control KrasG12D; Pdx1-Cre mice. Further, MUC5AC is not expressed in the normal colon, but it is de novo expressed during early stages and further increases during progression to advanced stages of colorectal malignancy. Despite association of increased MUC5AC levels with conventional and serrated ii neoplasia pathway of colorectal carcinogenesis, the diagnostic utility of MUC5AC for predicting future colorectal malignancy remained unexploited. Hence, we also explored the diagnostic utility of MUC5AC in conjunction with other differentially expressed mucins and mucin-associated glycans to predict colorectal malignancy. The study findings revealed an improved efficacy of combined MUC2, MUC5AC, and MUC17 expression for differentiating premalignant and/or malignant lesions from benign polyps. Furthermore, we addressed the problem of current non- availability of specific and sensitive markers to discriminate benign hyperplastic polyps from sessile serrated and tubular adenomas. We identified a combinatorial panel of mucins and glycoepitope based molecular markers (CA 19-9/MUC17/MUC5AC) that could discriminate sessile serrated adenoma/polyps and tubular adenomas from benign hyperplastic polyps with high sensitivity and specificity. Overall, our studies demonstrate that MUC5AC plays a key role in onset and progression of pancreatic cancer. Further, our findings indicate that in conjunction with other differentially expressed mucins and associated glycans, MUC5AC may significantly improve the early stage diagnosis of colorectal cancer. iii TABLE OF CONTENTS iv LIST OF FIGURES x LIST OF TABLES xii ABBREVIATIONS xiv ACKNOWLEDGEMENTS xxi iv TABLE OF CONTENTS Chapter I: Introduction Pg. No. A review on MUC5AC: Structure, and role of secretory mucin MUC5AC in benign and malignant pathologies 1. Introduction 2 2. Genomic organization, domain structure and functions 4 3. Expression and functions of MUC5AC 7 3.1 MUC5AC in physiological conditions 7 3.2 MUC5AC in Benign pathologies 8 3.2.A Allergic Rhinitis 8 3.2.B Chronic Rhinosinusitis 9 3.2.C Otitis media 9 3.2.D Chronic airway diseases 10 3.2.E Barrett’s esophagus 11 3.2.F Helicobacter pylori infections 12 3.2.G Pancreatitis 13 3.2.H Inflammatory bowel disease 13 3.3 MUC5AC and malignant diseases 14 3.3.A Salivary gland carcinomas 15 3.3.B Lung cancer 15 3.3.C Breast cancer 17 3.3.D Gastric cancer 17 3.3.E Gallbladder adenocarcinoma 18 3.3.F Cholangiocarcinoma 19 3.3.G Pancreatic cancer 20 v 3.3.G.a Pancreatic cancer diagnosis 22 3.3.G.b Pancreatic cancer therapy 23 3.3.H Colorectal cancer 24 3.3.I Ovarian cancer 26 3.3.J Cervical cancer 27 3.3.K Prostate cancer 28 3.3.L Urothelial bladder cancer 28 3.3.M Extramammary Paget’s disease 28 3.3.N Pseudomyxoma peritonei 29 4. Functional and mechanistic implications of MUC5AC in cancer 29 5. Muc5ac mice models 31 6. Regulation of MUC5AC expression 35 7. Hypoxia and MUC5AC 36 8. Smoking and MUC5AC 37 9. Conclusions and perspectives 39 References 48 General Hypothesis and objectives 71 Chapter II: Materials and Methods 73 1. Molecular basis of MUC5AC-mediated cell cycle regulation, metastatic properties, angiogenesis and chemoresistance of pancreatic cancer 74 1.A Immunohistochemistry 74 1.B Cell culture and transfections 75 1.C Immunoblotting 75 1.D Immunofluorescence/Confocal microscopy 76 1.E RNA extraction, RT-PCR, Q-PCR 77 vi 1.F MTT Assay 77 1.G Anchorage independent proliferation assay 78 1.H Apoptosis assay 78 1.I Cell cycle analysis 79 1.J Motility assay 79 1.K Cell adhesion assay 80 1.L Angiogenesis tube formation assay 80 1.M Co-immunoprecipitation 80 1.N Orthotopic implantation 81 1.O Subcellular fractionation 82 1.P Statistical analyses 82 2. Loss of Muc5ac mediated impact on pancreatic cancer progression in KRasG12D; Pdx1- Cre mouse model 83 2.A Generation of KrasG12D; Pdx1-Cre; Muc5ac-/- mouse model 83 2.B Immunohistochemistry (Mouse tissues) 83 2.C c-DNA isolation and genotyping 84 3. Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer 85 3.A Tissue specimens 85 3.B Immunohistochemistry (IHC) 85 3.C Statistical Analysis 86 4. Combinatorial assessment of CA 19-9/MUC17/MUC5AC expression discriminates sessile serrated adenoma/polyps and tubular adenoma from hyperplastic polyps 87 4.A Tissue specimens and patient demographics 87 4.B Immunohistochemistry (IHC) 87 vii 4.C Statistical analysis 88 References 95 Chapter III: Molecular basis of MUC5AC mediated cell cycle regulation, metastatic properties, angiogenesis and chemoresistance of pancreatic cancer cells 96 1. Synopsis 97 2. Background and rationale 98 3. Results 99 3.A MUC5AC is overexpressed in PC tissues and PC cell lines 99 3.B MUC5AC silencing decreased cell viability, anchorage-independent growth and induces apoptosis 100 3.C MUC5AC silencing induces G1/S phase cell cycle arrest 101 3.D MUC5AC confers resistance to Gemcitabine in pancreatic cancer cells 101 3.E MUC5AC knockdown reduces cell motility and adhesion to extracellular matrix proteins 103 3.F MUC5AC exists in a complex with E-Cadherin and β-Catenin 104 3.G Impact of MUC5AC expressing pancreatic cancer cells on endothelial cell viability and tube formation capacity 105 3.H Inhibition of MUC5AC in pancreatic cancer cells results in decreased tumorigenicity and metastasis in vivo 106 4. Discussion 106 References 131 Chapter IV: Loss of Muc5ac mediated impact on pancreatic cancer progression in KRasG12D; Pdx1-Cre mouse model 134 1. Synopsis 135 2. Background and rationale 136 viii 3. Results 137 3.A Breeding strategy and establishment of PDAC mice model with knockout 137 of Muc5ac 3.B Progression of PC in the KrasG12D; Pdx1-Cre; Muc5ac -/- mouse model 137 4. Discussion 139 References 150 Chapter V: Mucins (MUC5AC, MUC2, MUC17) and associated glycans (Tn/STn-MUC1) signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer 153 1. Synopsis 155 2. Background and rationale 156 3. Results 157 3.A Expression of transmembrane mucins 157 3.B Expression of secretory mucins 159 3.C Expression of mucin-associated glycans 160 3.D Multivariate analyses to evaluate biomarker combinations as predictors of malignancy 162 4. Discussion 163 References 184 Chapter VI: Combinatorial assessment of CA 19-9/MUC17/MUC5AC expression discriminates sessile serrated adenoma/polyp and tubular adenoma from hyperplastic polyps 189 1. Synopsis 190 2. Background
Recommended publications
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”
    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
    [Show full text]
  • The Mucin 5AC Level in Medical Faculty Students with Computer Vision Syndrome (CVS)
    ORIGINAL ARTICLE Bali Medical Journal (Bali Med J) 2019, Volume 8, Number 2: 460-463 P-ISSN.2089-1180, E-ISSN.2302-2914 The mucin 5AC level in medical faculty students with ORIGINAL ARTICLE Computer Vision Syndrome (CVS) Published by DiscoverSys CrossMark Doi: http://dx.doi.org/10.15562/bmj.v8i2.1425 I Gusti Ayu Made Juliari,1* Ratna Sari Dewi,1 Ni Luh Made Novi Ratnasari,2 Ariesanti Tri Handayani1 Volume No.: 8 ABSTRACT Introduction: Prolonged computer use will lead to a group of level which less than 186.33 ng/mL categorized as low mucin, while symptoms such as dryness of eyes, tired, headache and others called more than 186.33 ng/mL categorized as normal mucin level. Data was Issue: 2 Computer Vision Syndrome (CVS). The decrease of Mucin 5 AC (MUC5AC) analyzed by crosstabulation table and chi-square test with significant level could be one of the signs of dry eye disease on persons with CVS. value p < 0.05. Objective: The purpose of this study is to describe the Mucin 5AC Result: Most of the students who diagnosed with CVS had lower level in medical faculty students of Udayana University, Bali, Indonesia mucin 5AC levels as much as 77,3% and 33,3% students with CVS had First page No.: 460 with CVS. normal mucin 5AC level. This study analyses found there is significant Method: It is an observational cross-sectional analytic study at association between level of mucin 5AC with CVS. The students with Medical Faculty Udayana University on October 2018. Thirty four low level of mucin 5AC had 6,8 higher risk tend to be CVS (OR=6,8; CI P-ISSN.2089-1180 subject selected by purposive sampling and examined with Schirmer 95%= 1,42-32,37; p=0,012).
    [Show full text]
  • Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis
    International Journal of Molecular Sciences Review Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis Aldona Kasprzak 1,* and Agnieszka Adamek 2 1 Department of Histology and Embryology, Poznan University of Medical Sciences, Swiecicki Street 6, 60-781 Pozna´n,Poland 2 Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, University of Medical Sciences, Szwajcarska Street 3, 61-285 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-61-8546441; Fax: +48-61-8546440 Received: 25 February 2019; Accepted: 10 March 2019; Published: 14 March 2019 Abstract: Mucins are large O-glycoproteins with high carbohydrate content and marked diversity in both the apoprotein and the oligosaccharide moieties. All three mucin types, trans-membrane (e.g., MUC1, MUC4, MUC16), secreted (gel-forming) (e.g., MUC2, MUC5AC, MUC6) and soluble (non-gel-forming) (e.g., MUC7, MUC8, MUC9, MUC20), are critical in maintaining cellular functions, particularly those of epithelial surfaces. Their aberrant expression and/or altered subcellular localization is a factor of tumour growth and apoptosis induced by oxidative stress and several anti-cancer agents. Abnormal expression of mucins was observed in human carcinomas that arise in various gastrointestinal organs. It was widely believed that hepatocellular carcinoma (HCC) does not produce mucins, whereas cholangiocarcinoma (CC) or combined HCC-CC may produce these glycoproteins. However, a growing number of reports shows that mucins can be produced by HCC cells that do not exhibit or are yet to undergo, morphological differentiation to biliary phenotypes. Evaluation of mucin expression levels in precursors and early lesions of CC, as well as other types of primary liver cancer (PLC), conducted in in vitro and in vivo models, allowed to discover the mechanisms of their action, as well as their participation in the most important signalling pathways of liver cystogenesis and carcinogenesis.
    [Show full text]
  • Appendix 2. Significantly Differentially Regulated Genes in Term Compared with Second Trimester Amniotic Fluid Supernatant
    Appendix 2. Significantly Differentially Regulated Genes in Term Compared With Second Trimester Amniotic Fluid Supernatant Fold Change in term vs second trimester Amniotic Affymetrix Duplicate Fluid Probe ID probes Symbol Entrez Gene Name 1019.9 217059_at D MUC7 mucin 7, secreted 424.5 211735_x_at D SFTPC surfactant protein C 416.2 206835_at STATH statherin 363.4 214387_x_at D SFTPC surfactant protein C 295.5 205982_x_at D SFTPC surfactant protein C 288.7 1553454_at RPTN repetin solute carrier family 34 (sodium 251.3 204124_at SLC34A2 phosphate), member 2 238.9 206786_at HTN3 histatin 3 161.5 220191_at GKN1 gastrokine 1 152.7 223678_s_at D SFTPA2 surfactant protein A2 130.9 207430_s_at D MSMB microseminoprotein, beta- 99.0 214199_at SFTPD surfactant protein D major histocompatibility complex, class II, 96.5 210982_s_at D HLA-DRA DR alpha 96.5 221133_s_at D CLDN18 claudin 18 94.4 238222_at GKN2 gastrokine 2 93.7 1557961_s_at D LOC100127983 uncharacterized LOC100127983 93.1 229584_at LRRK2 leucine-rich repeat kinase 2 HOXD cluster antisense RNA 1 (non- 88.6 242042_s_at D HOXD-AS1 protein coding) 86.0 205569_at LAMP3 lysosomal-associated membrane protein 3 85.4 232698_at BPIFB2 BPI fold containing family B, member 2 84.4 205979_at SCGB2A1 secretoglobin, family 2A, member 1 84.3 230469_at RTKN2 rhotekin 2 82.2 204130_at HSD11B2 hydroxysteroid (11-beta) dehydrogenase 2 81.9 222242_s_at KLK5 kallikrein-related peptidase 5 77.0 237281_at AKAP14 A kinase (PRKA) anchor protein 14 76.7 1553602_at MUCL1 mucin-like 1 76.3 216359_at D MUC7 mucin 7,
    [Show full text]
  • MALE Protein Name Accession Number Molecular Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean H Mean PDAC Mean T-Test PDAC Vs. H T-Test
    MALE t-test t-test Accession Molecular H PDAC PDAC vs. PDAC vs. Protein Name Number Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean Mean Mean H CP PDAC/H PDAC/CP - 22 kDa protein IPI00219910 22 kDa 7 5 4 8 1 0 6 6 1 0.1126 0.0456 0.1 0.1 - Cold agglutinin FS-1 L-chain (Fragment) IPI00827773 12 kDa 32 39 34 26 53 57 36 30 55 0.0309 0.0388 1.8 1.5 - HRV Fab 027-VL (Fragment) IPI00827643 12 kDa 4 6 0 0 0 0 5 0 0 - 0.0574 - 0.0 - REV25-2 (Fragment) IPI00816794 15 kDa 8 12 5 7 8 9 10 6 8 0.2225 0.3844 1.3 0.8 A1BG Alpha-1B-glycoprotein precursor IPI00022895 54 kDa 115 109 106 112 111 100 112 109 105 0.6497 0.4138 1.0 0.9 A2M Alpha-2-macroglobulin precursor IPI00478003 163 kDa 62 63 86 72 14 18 63 79 16 0.0120 0.0019 0.2 0.3 ABCB1 Multidrug resistance protein 1 IPI00027481 141 kDa 41 46 23 26 52 64 43 25 58 0.0355 0.1660 2.4 1.3 ABHD14B Isoform 1 of Abhydrolase domain-containing proteinIPI00063827 14B 22 kDa 19 15 19 17 15 9 17 18 12 0.2502 0.3306 0.7 0.7 ABP1 Isoform 1 of Amiloride-sensitive amine oxidase [copper-containing]IPI00020982 precursor85 kDa 1 5 8 8 0 0 3 8 0 0.0001 0.2445 0.0 0.0 ACAN aggrecan isoform 2 precursor IPI00027377 250 kDa 38 30 17 28 34 24 34 22 29 0.4877 0.5109 1.3 0.8 ACE Isoform Somatic-1 of Angiotensin-converting enzyme, somaticIPI00437751 isoform precursor150 kDa 48 34 67 56 28 38 41 61 33 0.0600 0.4301 0.5 0.8 ACE2 Isoform 1 of Angiotensin-converting enzyme 2 precursorIPI00465187 92 kDa 11 16 20 30 4 5 13 25 5 0.0557 0.0847 0.2 0.4 ACO1 Cytoplasmic aconitate hydratase IPI00008485 98 kDa 2 2 0 0 0 0 2 0 0 - 0.0081 - 0.0
    [Show full text]
  • Proteomic Analysis of Cancer and Mesothelial Cells Reveals an Increase in Mucin 5AC During Ovarian Cancer and Peritoneal Interaction
    JOURNAL OF PROTEOMICS 103 (2014) 204– 215 Available online at www.sciencedirect.com ScienceDirect www.elsevier.com/locate/jprot Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction Natasha Musrapa,b, George S. Karagiannisa,b, Punit Saraona,b, Ihor Batruchb, Chris Smithc, Eleftherios P. Diamandisa,b,c,⁎ aDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada bDepartment of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada cDepartment of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada ARTICLE INFO ABSTRACT Article history: Ovarian cancer is a highly metastatic disease that is often characterized by widespread Received 4 December 2013 abdominal dissemination. A hallmark of ovarian cancer progression is the attachment of Accepted 27 March 2014 malignant cells to the mesothelium and the formation of invasive peritoneal implants. Available online 12 April 2014 Therefore, delineating factors involved in cancer-peritoneal cell interaction is critical to improving patient survival, as it may lead to the discovery of novel therapeutic targets. As Keywords: such, we aimed to identify proteins that participate in this interaction by comparing the Ovarian cancer secreted proteome of a co-culture model containing ovarian cancer (OVCAR-5) and mesothelial Proteomics cells (LP-9), to their respective monoculture secretomes. In total, 49 proteins were differentially Co-culture secreted during cancer and mesothelial cell contact. Relative mRNA expression of candidates Peritoneum was performed, which revealed a significant increase in MUC5AC gene expression in cancer Metastasis cells cultured in three different co-culture models (OVCAR-5 and LP-9; BG-1 and LP-9; OV-90 and Mucin 5AC LP-9).
    [Show full text]
  • Supp Table 6.Pdf
    Supplementary Table 6. Processes associated to the 2037 SCL candidate target genes ID Symbol Entrez Gene Name Process NM_178114 AMIGO2 adhesion molecule with Ig-like domain 2 adhesion NM_033474 ARVCF armadillo repeat gene deletes in velocardiofacial syndrome adhesion NM_027060 BTBD9 BTB (POZ) domain containing 9 adhesion NM_001039149 CD226 CD226 molecule adhesion NM_010581 CD47 CD47 molecule adhesion NM_023370 CDH23 cadherin-like 23 adhesion NM_207298 CERCAM cerebral endothelial cell adhesion molecule adhesion NM_021719 CLDN15 claudin 15 adhesion NM_009902 CLDN3 claudin 3 adhesion NM_008779 CNTN3 contactin 3 (plasmacytoma associated) adhesion NM_015734 COL5A1 collagen, type V, alpha 1 adhesion NM_007803 CTTN cortactin adhesion NM_009142 CX3CL1 chemokine (C-X3-C motif) ligand 1 adhesion NM_031174 DSCAM Down syndrome cell adhesion molecule adhesion NM_145158 EMILIN2 elastin microfibril interfacer 2 adhesion NM_001081286 FAT1 FAT tumor suppressor homolog 1 (Drosophila) adhesion NM_001080814 FAT3 FAT tumor suppressor homolog 3 (Drosophila) adhesion NM_153795 FERMT3 fermitin family homolog 3 (Drosophila) adhesion NM_010494 ICAM2 intercellular adhesion molecule 2 adhesion NM_023892 ICAM4 (includes EG:3386) intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)adhesion NM_001001979 MEGF10 multiple EGF-like-domains 10 adhesion NM_172522 MEGF11 multiple EGF-like-domains 11 adhesion NM_010739 MUC13 mucin 13, cell surface associated adhesion NM_013610 NINJ1 ninjurin 1 adhesion NM_016718 NINJ2 ninjurin 2 adhesion NM_172932 NLGN3 neuroligin
    [Show full text]
  • Proteomic Identification of Mediators Implicated in the Metastatic Progression of Ovarian Cancer
    Proteomic Identification of Mediators Implicated in the Metastatic Progression of Ovarian Cancer by Natasha Musrap A thesis submitted in conformity with the requirements for the degree of Doctorate of Philosophy Department of Laboratory Medicine and Pathobiology University of Toronto © Copyright by Natasha Musrap 2015 Proteomic Identification of Mediators Implicated in the Metastatic Progression of Ovarian Cancer Natasha Musrap Doctor of Philosophy Laboratory Medicine and Pathobiology University of Toronto 2015 Abstract Ovarian cancer (OvCa) is the leading cause of death among gynecological malignancies, and is characterized by peritoneal metastasis and increased resistance to chemotherapy. Acquired drug resistance is often attributed to the formation of multicellular aggregates (MCAs) in the peritoneal cavity, which seed abdominal surfaces, particularly, the mesothelial lining of the peritoneum. Given that the presence of metastatic implants is a predictor of poor survival, a better understanding of the underlying biology surrounding OvCa metastasis may lead to the identification of key molecules that are integral to the progression of the disease, which therefore, may serve as practicable therapeutic targets. To that end, in vitro cell line models of cancer-peritoneal interaction and aggregate formation were used to identify proteins that are differentially expressed during cancer progression, using mass spectrometry-based approaches. First, we performed a proteomics analysis of a co-culture model of ovarian cancer and mesothelial cells, in which we identified numerous proteins that were differentially regulated during cancer-peritoneal interaction. We further validated one protein, MUC5AC, and confirmed its expression at the cancer-peritoneal interface. Next, we conducted a quantitative proteomics analysis of a cell line grown as a monolayer and as MCAs.
    [Show full text]
  • Reconsidering the Central Role of Mucins in Dry Eye and Ocular Surface Diseases T
    Progress in Retinal and Eye Research 71 (2019) 68–87 Contents lists available at ScienceDirect Progress in Retinal and Eye Research journal homepage: www.elsevier.com/locate/preteyeres Reconsidering the central role of mucins in dry eye and ocular surface diseases T ∗ Christophe Baudouina, ,1, Maurizio Rolandob,1, Jose M. Benitez Del Castilloc,1, Elisabeth M. Messmerd,1, Francisco C. Figueiredoe,1, Murat Irkecf,1, Gysbert Van Setteng,1, Marc Labetoulleh,1 a Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, University Versailles Saint Quentin en Yvelines, Paris, France b Ocular Surface & Dry Eye Center, ISPRE Ophthalmics, Genoa, Italy c University Complutense, Hospital Clinico San Carlos, Clinica Rementeria, Madrid, Spain d Department of Ophthalmology, Ludwig-Maximilians-University, Munich, Germany e Department of Ophthalmology, Royal Victoria Infirmary and Institute of Genetic Medicine, Newcastle University, Newcastle Upon Tyne, UK f Department of Ophthalmology, Hacettepe Faculty of Medicine, Ankara, Turkey g St. Eriks Eye Hospital, Stockholm, Sweden h Hôpital Bicêtre, APHP, South Paris University, Ophthalmology, Le Kremlin-Bicêtre, France ARTICLE INFO ABSTRACT Keywords: Mucins are key actors in tear film quality and tear film stability. Alteration of membrane-bound mucin ex- Mucins pression on corneal and conjunctival epithelial cells and/or gel-forming mucin secretion by goblet cells (GCs) Goblet cells promotes in ocular surface diseases and dry eye disease (DED). Changes in the mucin layer may lead to enhanced Ocular surface tear evaporation eventually contributing to tear hyperosmolarity which has been associated with ocular surface Dry eye disease inflammation. Inflammatory mediators in turn may have a negative impact on GCs differentiation, proliferation, Ocular inflammation and mucin secretion.
    [Show full text]
  • The Investigation of Lactoferrin Nitration: Quantification, Unction,F and Inhibition
    University of Denver Digital Commons @ DU Electronic Theses and Dissertations Graduate Studies 1-1-2018 The Investigation of Lactoferrin Nitration: Quantification, unction,F and Inhibition Amani Yahya Alhalwani University of Denver Follow this and additional works at: https://digitalcommons.du.edu/etd Part of the Biochemistry Commons, and the Environmental Chemistry Commons Recommended Citation Alhalwani, Amani Yahya, "The Investigation of Lactoferrin Nitration: Quantification, unction,F and Inhibition" (2018). Electronic Theses and Dissertations. 1452. https://digitalcommons.du.edu/etd/1452 This Dissertation is brought to you for free and open access by the Graduate Studies at Digital Commons @ DU. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ DU. For more information, please contact [email protected],[email protected]. THE INVESTIGATION OF LACTOFERRIN NITRATION: QUANTIFICATION, FUNCTION, AND INHIBITION __________ A Dissertation Presented to the Faculty of Natural Sciences and Mathematics University of Denver __________ In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy __________ by Amani Yahya Alhalwani June 2018 Advisor: John Alexander Huffman, PhD ©Copyright by Amani Yahya Alhalwani 2018 All Rights Reserved Author: Amani Yahya Alhalwani Title: THE INVESTIGATION OF LACTOFERRIN NITRATION: QUANTIFICATION, FUNCTION, AND INHIBITION Advisor: John Alexander Huffman, PhD Degree Date: June 2018 Abstract Lactoferrin (LF) is an iron-binding glycoprotein of molecular mass ca. 80 kDa that is predominantly found in mammalian body fluids. Lactoferrin is a multifunctional protein that has a wide range of properties such as antibacterial, antiviral, anti- inflammatory, and anti-allergic functions. Tyrosine residues in the protein play a part in many lactoferrin functions.
    [Show full text]
  • CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing
    Published OnlineFirst April 12, 2017; DOI: 10.1158/0008-5472.CAN-16-3351 Cancer Molecular and Cellular Pathobiology Research CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma Toyoki Yoshimoto1,2, Miwa Tanaka1, Mizuki Homme1, Yukari Yamazaki1, Yutaka Takazawa3, Cristina R. Antonescu4, and Takuro Nakamura1 Abstract CIC-DUX4 sarcoma (CDS) or CIC-rearranged sarcoma is a short spindle cells. Gene-expression profiles of CDS and eMC subcategory of small round cell sarcoma resembling the morpho- revealed upregulation of CIC-DUX4 downstream genes such as logical phenotypes of Ewing sarcoma (ES). However, recent PEA3 family genes, Ccnd2, Crh, and Zic1. IHC analyses for both clinicopathologic and molecular genetic analyses indicate that mouse and human tumors showed that CCND2 and MUC5AC CDS is an independent disease entity from ES. Few ancillary are reliable biomarkers to distinguish CDS from ES. Gene silenc- markers have been used in the differential diagnosis of CDS, and ing of CIC-DUX4 as well as Ccnd2, Ret, and Bcl2 effectively additional CDS-specific biomarkers are needed for more defini- inhibited CDS tumor growth in vitro. The CDK4/6 inhibitor tive classification. Here, we report the generation of an ex vivo palbociclib and the soft tissue sarcoma drug trabectedin also mouse model for CDS by transducing embryonic mesenchymal blocked the growth of mouse CDS. In summary, our mouse cells (eMC) with human CIC-DUX4 cDNA. Recipient mice trans- model provides important biological information about CDS planted with eMC-expressing CIC-DUX4 rapidly developed an and provides a useful platform to explore biomarkers and ther- aggressive, undifferentiated sarcoma composed of small round to apeutic agents for CDS.
    [Show full text]
  • Mucin Dynamics and Enteric Pathogens
    FOCUS ON MUCOSAL MICROBIOLOGYREVIEWS Mucin dynamics and enteric pathogens Michael A. McGuckin*, Sara K. Lindén‡, Philip Sutton§ and Timothy H. Florin* Abstract | The extracellular secreted mucus and the cell surface glycocalyx prevent infection by the vast numbers of microorganisms that live in the healthy gut. Mucin glycoproteins are the major component of these barriers. In this Review, we describe the components of the secreted and cell surface mucosal barriers and the evidence that they form an effective barricade against potential pathogens. However, successful enteric pathogens have evolved strategies to circumvent these barriers. We discuss the interactions between enteric pathogens and mucins, and the mechanisms that these pathogens use to disrupt and avoid mucosal barriers. In addition, we describe dynamic alterations in the mucin barrier that are driven by host innate and adaptive immune responses to infection. Commensal microorganism An enormous surface area of mucosal epithelial cells in consists of a single layer of columnar epithelial cells A microorganism living in a the gastrointestinal tract is potentially exposed to enteric covered by a layer of secreted mucus that is at its thick­ mutually advantageous microorganisms. The mucosal epithelium has highly est in the stomach and colon. This is the major barrier relationship with a mammalian specialized functions throughout the gastrointestinal separating the epithelial cells and underlying host tissues host (for example, in the lumen tract to allow ingested food to be digested,
    [Show full text]